BioSpace

Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.

بقلم BioSpace

1 دقيقة قراءة
مشاركة
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

هل لديك أخبار لمشاركتها مع صناعة الفعاليات؟

أرسل بياناً صحفياً أو تلميحاً بقصة وتواصل مع آلاف المهنيين في مجال الفعاليات.

تواصل معنا→

المزيد في Health Tech

رؤى ذات صلة